New Market - January 19, 2018
Approval for Lynparza in Japan
AstraZeneca and Merck & Co announces that the Japanese Ministry of Health, Labour and Welfare has approved Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded to their last platinum-based chemotherapy. Lynparza is the first poly ADP-ribose polymerase (PARP) inhibitor to be […]
Intellectual Property - January 10, 2018
Cantargia receives patent approval in China
The Chinese patent office, the State Intellectual Property Office, has formally approved the company’s patent application for IL1RAP as target molecule for antibody therapy of several types of solid tumours. Cantargia is developing antibodies against IL1RAP for treatment of life-threatening diseases. The company’s main project, the immuno-oncology antibody CAN04, which Nordic Life Science previously has […]
MedTech Business - November 13, 2017
Sectra strengthens its presence in Saudi Arabia
Sectra has entered into a partnership with El Seif Development Company. Through this distribution agreement, Sectra aims to strengthen its future business capabilities in Saudi Arabia. Sectra also established a regional service and support company, Sectra Saudi Arabia. “The combination of establishing a regional Sectra support organization and utilizing the strong market knowledge and network of […]
MedTech Business - November 9, 2017
SciBase receives 1 MSEK order
The company has signed a new distribution agreement in Italy with International Health and Fitness Organisation AB (IHFO), a Swedish distributor active in Italy, within a completely new customer segment. As part of the signing, SciBase received an initial order of approx. 0.5 million SEK consisting of Nevisense systems and single use electrodes for delivery during the fourth quarter 2017. […]
New Market - October 26, 2017
Sobi ‘s Alprolix approved in Saudi Arabia
Swedish Orphan Biovitrum announces that the Saudi Food & Drug Authority in the Kingdom of Saudi Arabia has approved Alprolix (eftrenonacog alfa), for the treatment of haemophilia B. Alprolix is the first extended half-life and recombinant factor IX Fc fusion protein therapy approved for the treatment of haemophilia B in Saudi Arabia. “We are very pleased Alprolix is […]
New Market - October 2, 2017
Approval for Genmab’s DARZALEX in Japan
The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the use of DARZALEX (daratumumab) in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma. D ARZALEX is being developed under an August 2012 agreement in which Genmab granted Janssen Biotech, Inc. an […]
